Inicio>>Signaling Pathways>> Cell Cycle/Checkpoint>> Microtubule/Tubulin>>BNC105

BNC105

Catalog No.GC34102

BNC105 es un inhibidor de la polimerizaciÓn de tubulina con potentes propiedades antiproliferativas y disruptoras vasculares tumorales.

Products are for research use only. Not for human use. We do not sell to patients.

BNC105 Chemical Structure

Cas No.: 945771-74-4

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
297,00 $
Disponible
5mg
270,00 $
Disponible
10mg
386,00 $
Disponible
50mg
1.157,00 $
Disponible
100mg
1.620,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BNC105 is a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.

[1]. Flynn BL, et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem. 2011 Sep 8;54(17):6014-27. [2]. Kremmidiotis G, et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther. 2010 Jun;9(6):1562-73. [3]. Inglis DJ, et al. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer. Cancer Biol Ther. 2014;15(11):1552-60.

Reseñas

Review for BNC105

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BNC105

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.